Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Introduction: Systemic therapy and cytoreduction (CRS) with hyperthermic intra‐peritoneal chemotherapy (HIPEC) may benefit selected patients with carcinomatosis from colon cancer (PC). This study presents the results of a consecutive series of patients evaluated under a single strategy. Patients and Methods: Forty patients with PC referred for CRS were evaluated. Evaluation of their treatment was determined according to disease severity scored on a 3‐point scale including: (1) symptoms, (2) extent of peritoneal dissemination (PCI), and (3) primary tumor histology. Overall survival (OS) was analyzed using Kaplan–Meier product‐limit method and log rank testing according to four tiers of estimated disease severity based on the above parameters. Results: For patients with disease severity score I, II, III, and IV, 2‐year OS following treatment was 100%, 80%, 80%, and 0%, respectively. Median OS with most advanced disease (IV: n = 20) was 5 months versus 36 months for disease of lesser severity (I–III: n = 20;P < 0.001; RR = 0.2; 95%CI 0.1–0.5). Advanced disease (IV) was an independent predictor of adverse outcome on multivariate analysis with 2.6‐fold increased likelihood of mortality. Conclusion: A treatment strategy based on disease severity determined at time of diagnosis, stratifies patients into prognostic groups and may improve selection of patients for appropriate therapy. J. Surg. Oncol. 2009;99:9–15. Published 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Metadata
- Authors
- Pelz, J. O. W., Stojadinovic, A., Nissan, A., Hohenberger, W., & Esquivel, J.
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2008-10-20
- Volume
- 99
- Issue
- 1
- Pages
- 9-15
- ISSN
- 0022-4790 (ISSN-L)
- 1096-9098
- OpenAlex
- W2015517235
- Cited by
- 165
- References
- 4
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. https://app.cochat.ai/papers/10.1002/jso.21169
- The paper
- Pelz, J. O. W., Stojadinovic, A., Nissan, A., Hohenberger, W., & Esquivel, J. (2009). Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. Journal of Surgical Oncology. https://doi.org/10.1002/jso.21169
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.